Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Latrotoxin refers to a family of large, presynaptic, pore-forming neurotoxin proteins found in the venom of Latrodectus (black widow) spiders[1][3][4][5]. This protein family (including α-latrotoxin, β-latroinsectotoxin, γ-latroinsectotoxin, δ-latroinsectotoxin, ε-latroinsectotoxin, and α-latrocrustatoxin) targets specific nervous system receptors in animal prey. The best studied member, α-latrotoxin, is vertebrate-specific and causes the clinical syndrome latrodectism in humans. Latrotoxins bind specific neuronal receptors—primarily neurexins, latrophilins, and protein tyrosine phosphatase σ—oligomerize, and assemble into tetrameric pores in the cell membrane. This leads to a massive, uncontrolled release of neurotransmitters by permitting Ca²⁺ influx, ultimately resulting in severe neurotoxic symptoms. Though of high scientific interest as molecular probes and for their unique mechanism, latrotoxins as a group are not considered therapeutic targets; rather, they are the molecular agents of the spider’s toxic effects[1][3][4][5]. “Latrodectus venom toxin” is not a precise canonical molecular or receptor name but rather refers collectively to multiple related proteins—each with specific targets and activities. The correct molecular targets (e.g., α-latrotoxin) should be specified for precise scientific or drug discovery work[1][3][4][5].
Binds specific neuronal receptors (e.g., neurexins, latrophilins, PTPσ) and inserts into membranes as a tetramer, forming Ca²⁺-permeable pores that trigger uncontrolled neurotransmitter release[1][3][5]. Receptor activation leading to intracellular signaling causing exocytosis[5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Latrotoxin.